China Aoxing Receives Approval to Manufacture Tilidine
Posted on: Monday, 26 November 2007, 12:01 CST
China Aoxing Pharmaceutical has reported that the China State Food & Drug Administration has granted the company designated manufacturer status to produce Tilidine tablets and capsules, a highly regulated narcotic drug, for the treatment of cancer pain in China.
Tilidine is a prodrug, which, following oral administration, is converted to the active analgesic metabolite, nortilidine. Tilidine is indicated for the relief of acute, moderate to severe pain, and chronic cancer-related pain. Currently Tilidine is not available in China and will be introduced by China Aoxing to the China market.
Zhenjiang Yue, the CEO of CAXG, said: "We expect to launch this important and needed cancer pain medicine through CAXG's integrated 500-person sales force in later 2008. Our mission is to bring multiple effective therapeutic options, including Oxycodone, Tilidine and other promising narcotic pain medicines in our pipeline, to help approximately 20 million cancer patients in China."
Source: Datamonitor
Related Articles
- Strategies For Reducing Painful Breast Cancer Drug Side Effects
- First Results From Major European Patient Survey Show Devastating Impact of Living With Breakthrough Cancer Pain
- Novelos Therapeutics and Lee's Pharmaceutical Sign Exclusive Collaboration Agreement in China for Novelos' Cancer and Hepatitis Compounds
- Cancer Pain Often Left Untreated
- China's longest river "cancerous" with pollution
- China's Longest River 'Cancerous' with Pollution
- Cephalon's Fentanyl Effervescent Buccal Tablet Reduces Intensity of Breakthrough Pain in Cancer Patients
- Pollution Turns China Village into Cancer Cluster
- Cephalon Files New Drug Application for OraVescent(R) Fentanyl for the Management of Breakthrough Pain in Cancer Patients
- Synthetic Venom May Help to Relieve Cancer Pain
 |
 |
User Comments (0)
RSS Feeds